Glenmark launches COVID-19 nasal spray in India

9 February 2022
glenmark-pharmaceuticals-big

Since the early days of the pandemic, a number of developers have  pursued the concept of using a nasal spray to administer anti-virals for treatment and prevention of coronavirus.

In India, one such product has now been approved and launched, marketed by Mumbai-based Glenmark Pharmaceuticals (BSE: 532296), in collaboration with Canada’s SaNOtize.

The firms are offering a nitric oxide nasal spray under the brand name FabiSpray, for the treatment of adults with COVID-19 who have high risk of progression of the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical